

# **Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/K5F6584DBE13EN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: K5F6584DBE13EN

## **Abstracts**

The 7 major keratitis markets are expected to exhibit a CAGR of 5.04% during 2024-2034.

The keratitis market has been comprehensively analyzed in IMARC's new report titled "Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Keratitis refers to an inflammation or infection of the cornea, the transparent, dome-shaped surface that covers the front of the eye. This condition mainly damages the external structures of the eye, such as the cornea and the surrounding tissues. The symptoms of the disease include eye pain and discomfort, redness, blurred vision, sensitivity to light (photophobia), excessive tearing or discharge, the feeling of a foreign body in the eye, etc. In severe cases, individuals suffering from the ailment may also experience corneal ulcers or perforations, leading to vision loss or even blindness. The diagnosis of keratitis typically involves a comprehensive eye examination, including a detailed medical history and evaluation of symptoms. A healthcare provider will also perform a slit-lamp examination that helps to identify the presence of infiltrates, such as inflammatory cells or infectious agents, in patients. If an infection is suspected as the cause of keratitis, a corneal culture is further recommended to determine the specific microorganism triggering the illness. Additionally, anterior segment photography is utilized to detect the extent and progression of the disease.

The rising incidences of bacterial, viral, fungal, or parasitic infections, in which the microorganisms directly invade the cornea, leading to damage and inflammation, are primarily driving the keratitis market. In addition to this, the increasing prevalence of various associated risk factors, like dry eyes, exposure to irritants, autoimmune disorders, eye injury or trauma, allergic reactions, etc., is further acting as a significant

growth-inducing factor. Moreover, the inflating utilization of effective drugs, such as antibiotics, antifungals, antivirals, etc., to treat the infection and inhibit disease progression in patients is also creating a positive outlook for the market. Additionally, the widespread application of artificial tears or lubricating eye drops, since they help to maintain a stable and healthy tear film by moisturizing the ocular surface and reducing discomfort, is further propelling the market growth. Besides this, the emerging popularity of phototherapeutic keratectomy, which involves using an excimer laser to precisely remove the superficial layers of the cornea, thereby eliminating the infected or scarred tissue and promoting the regeneration of robust cells, is expected to drive the keratitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the keratitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for keratitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the keratitis market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

## Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the keratitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the keratitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current keratitis marketed drugs and late-stage pipeline drugs.

## In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report:

Market Insights

How has the keratitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the keratitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the keratitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of keratitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of keratitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of keratitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with keratitis across the seven major markets?

What is the size of the keratitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of keratitis?

What will be the growth rate of patients across the seven major markets?

## Keratitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for keratitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the keratitis market?

What are the key regulatory events related to the keratitis market?

What is the structure of clinical trial landscape by status related to the keratitis market?

What is the structure of clinical trial landscape by phase related to the keratitis market?

What is the structure of clinical trial landscape by route of administration related to the keratitis market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 KERATITIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 KERATITIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 KERATITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 KERATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 KERATITIS - UNMET NEEDS**

## **10 KERATITIS - KEY ENDPOINTS OF TREATMENT**

## **11 KERATITIS - MARKETED PRODUCTS**

- 11.1 List of Keratitis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Oxervate (Cenegermin) - Dompe Farmaceutici
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.



## **12 KERATITIS - PIPELINE DRUGS**

### 12.1 List of Keratitis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 CSB001 - Claris Biotherapeutics

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

#### 12.1.2 Udonitrectag - Recordati Rare Diseases

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

#### 12.1.3 SygeLIX Coll T - TBF Genie Tissulaire

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

#### 12.1.4 RGN 259 - RegeneRx Biopharmaceuticals

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. KERATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. KERATITIS – CLINICAL TRIAL LANDSCAPE**

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

## 14.4 Key Regulatory Events

## **15 KERATITIS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Keratitis - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Keratitis - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Keratitis - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Keratitis - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Keratitis - Access and Reimbursement Overview

### 15.4 Market Scenario - Germany

#### 15.4.1 Keratitis - Market Size

##### 15.4.1.1 Market Size (2018-2023)

##### 15.4.1.2 Market Forecast (2024-2034)

#### 15.4.2 Keratitis - Market Size by Therapies

##### 15.4.2.1 Market Size by Therapies (2018-2023)

##### 15.4.2.2 Market Forecast by Therapies (2024-2034)

#### 15.4.3 Keratitis - Access and Reimbursement Overview

### 15.5 Market Scenario - France

#### 15.5.1 Keratitis - Market Size

##### 15.5.1.1 Market Size (2018-2023)

##### 15.5.1.2 Market Forecast (2024-2034)

#### 15.5.2 Keratitis - Market Size by Therapies

##### 15.5.2.1 Market Size by Therapies (2018-2023)

##### 15.5.2.2 Market Forecast by Therapies (2024-2034)

#### 15.5.3 Keratitis - Access and Reimbursement Overview

### 15.6 Market Scenario - United Kingdom

#### 15.6.1 Keratitis - Market Size

##### 15.6.1.1 Market Size (2018-2023)

- 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 Keratitis - Market Size by Therapies
  - 15.6.2.1 Market Size by Therapies (2018-2023)
  - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Keratitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Keratitis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Keratitis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Keratitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Keratitis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Keratitis - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Keratitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Keratitis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Keratitis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Keratitis - Access and Reimbursement Overview

## **16 KERATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 KERATITIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 KERATITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/K5F6584DBE13EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K5F6584DBE13EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

